Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-06T02:06:10.020Z Has data issue: false hasContentIssue false
  • English
  • Français

The chemotherapy of Plasmodium berghei. I. Resistance to drugs

Published online by Cambridge University Press:  06 April 2009

June P. Thurston
June P. Thurston
Affiliation:
The National Institute for Medical Research, London, and the Molteno Institute, University of Cambridge
Get access Rights & Permissions [Opens in a new window]

Extract

1. Strains of P. berghei resistant to sulphadiazine, pyrimethamine, and methylene blue were produced by treating acute infections with low doses of drug.

2. The strain resistant to methylene blue was sensitive to pamaquin, mepacrine, sulphadiazine, proguanil, pyrimethamine, and 2 : 4-diamino-6 : 7-camphano-pteridine.

3. The pyrimethamine-resistant strain was cross-resistant to proguanil and its active metabolite CPT, 2 : 4-diamino-6 : 7-camphanopteridine, 2 : 4-diamino-6 : 7-(l′-ethylindolo)-pteridine, and 2 : 4-diamino-5-p-chlorophenylpyrimidine.

4. The sulphadiazine-resistant strain was cross-resistant to pyrimethamine, sulphanilamide, proguanil and its active metabolite CPT, 2 : 4-diamino-6 : 7-dinhexylpteridine, and 2 : 4-diamino-6 : 7-diisopropylpteridine. It was as sensitive as the parent strain to quinine, mepacrine, chloroquin, pamaquin, methylene blue, and M 3349.

5. The action of sulphadiazine against the sulphadiazine-resistant strain was inhibited by the same doses of p-aminobenzoic acid and folic acid as were required with the parent strain, although the dose of sulphadiazine was increased 30-fold.

Type
Research Article
Information
Parasitology , Volume 43 , Issue 3-4 , November 1953 , pp. 246 - 252
Copyright
Copyright © Cambridge University Press 1953

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Bishop, A. & Birkett, B. (1947). Acquired resistance to Paludrine in Plasmodium gallinaceum. Nature, Lond., 159, 884.CrossRefGoogle ScholarPubMed
Bishop, A. & Birkett, B. (1948). Drug-resistance in Plasmodium gallinaceum, and the persistence of Paludrine-resistance after mosquito transmission. Parasitology, 39, 125.CrossRefGoogle ScholarPubMed
Bishop, A. & McConnachie, E. W. (1948). Resistance to sulphadiazine and ‘paludrine’ in the malaria parasite of the fowl (Plasmodium gallinaceum). Nature, Lond., 162, 541.CrossRefGoogle Scholar
Bishop, A. & McConnachie, E. W. (1950 a). Sulpha-diazine-resistance in Plasmodium gallinaceum and its relation to other antimalarial compounds. Parasitology, 40, 163.CrossRefGoogle ScholarPubMed
Bishop, A. & McConnachie, E. W. (1950 b). Cross-resistance between sulphanilamide and paludrine (proguanil) in a strain of Plasmodium gallinaceum resistant to sulphanilamide. Parasitology, 40, 175.CrossRefGoogle Scholar
Bishop, A. & McConnachie, E. W. (1953). The development of resistance to metachloridine in Plasmodium gallinaceum in chicks. Parasitology, 42, 277.Google Scholar
Carrington, H. C., Crowther, A. F., Davey, D. G., Levi, A. A. & Rose, F. L. (1951). A metabolite of ‘Paludrine’ with high antimalarial activity. Nature, Lond., 168, 1080.Google Scholar
Chase, B. H., Thurston, J. P. & Walker, J. (1951). Antimalarial activity in 2:4-diamino-5-arylpyrimidines. Some reactions of α-formylphenylacetonitrile. J. chem. Soc. p. 3439.Google Scholar
Collier, H. O. J. & Waterhouse, P. D. (1950). Studies in the chemotherapy of cholera. II. In vitro vibrio-static properties of certain 2:4-diaminopteridines. Ann. Trop. Med. Parasit. 44, 156.Google Scholar
Collier, H. O. J. & Waterhouse, P. D. (1952). The activities of some 2:4-diaminopteridines and sulpha-thiazole against Streptococcus faecalis and Staphylococcus aureus. Brit. J. Pharmacol. 7, 161.Google ScholarPubMed
Cooper, W. C., Coatney, G. R. & Imboden, C. A. Jr. (1950). Studies in human malaria. XXIII. Acquired resistance to chlorguanide in the Chesson strain of Plasmodium vivax. J. nat. Malaria Soc. 9, 59.Google Scholar
Crowther, A. F. & Levi, A. A. (1953). Proguanil—the isolation of a metabolite with high antimalarial activity. Brit. J. Pharmacol. 8, 93.Google Scholar
Greenberg, J. (1949). Hypersensitivity to sulfadiazine of a chlorguanide-resistant strain of Plasmodium gallinaceum. J. Nat. Malaria Soc. 8, 80.Google Scholar
Greenberg, J. & Richeson, E. M. (1951). Effect of 2:4-diamino-5-(p−chlorophenoxy)-6-methylpyrimidine and 2:4-diamino-6:7-diphenylpteridine on chlorguanide-resistant strain of Plasmodium gallinaceum. Proc. Soc. Exp. Biol., N.Y., 77, 174.Google Scholar
Hawking, F. & Thurston, J. P. (1951). A strain of monkey malaria (Plasmodium cynomolgi) made resistant to proguanil (Paludrine). Trans. R. Soc. Trop. Med. Hyg. 44, 695.Google Scholar
Ivánovics, G. (1942). Ueber den Wirkungsmechanismus des p−Aminobenzolsulfamids und seiner Derivate. Z. ImmunForsch. 101, 58.Google Scholar
Landy, M., Larkum, N. W., Oswald, E. J. & Streight-off, F. (1943). Increased production of p−amino-benzoic acid associated with the development of sulfonamide resistance in Staphylococcus aureus. Science, 97, 265.Google Scholar
McConnachie, E. W. (1953). The action of 2:4-diamino-6:7-didisopropylpteridine on normal, proguanil- and sulphadiazine-resistant strains of Plasmodium gallinaceum. Parasitology, 42, 272.CrossRefGoogle ScholarPubMed
Robertson, G. I., Davey, D. G. & Fairley, N. H. (1952). Cross-resistance between ‘Daraprim’ and proguanil. Brit. Med. J. 2, 1255.Google Scholar
Rollo, I. M. (1951). A 2:4-diaminopyrimidine in the treatment of proguanil-resistant laboratory malarial strains. Nature, Lond., 168, 332.CrossRefGoogle Scholar
Rollo, I. M. (1952 a). Daraprim—experimental chemotherapy. Trans. R. Soc. Trop. Med. Hyg. 46, 474.CrossRefGoogle ScholarPubMed
Rollo, I. M. (1952 b). ‘Daraprim’ resistance in experimental malarial infections. Nature, Lond., 170, 415.Google Scholar
Schmidt, L. H. & Genther, C. S. (1953). The antimalarial properties of 2:4-diamino-5-p−chlorophenyl-6-ethylpyrimidine (Daraprim). J. Pharmacol. 107, 61.Google Scholar
Schmidt, L. H., Genther, C. S., Fradkin, R. & Squires, W. (1949). Development of resistance to chlorguanide (Paludrine) during treatment of infections with Plasmodium cynomolgi. J. Pharmacol. 95, 382.Google ScholarPubMed
Singh, J., Ray, A. P., Basu, P. C. & Nair, C. P. (1952). Acquired resistance to proguanil in Plasmodium knowlesi. Trans. Soc. Trop. Med. Hyg. 46, 639.Google Scholar
Spink, W. W., Wright, L. D., Vivino, J. J. & Skeggs, H. R. (1944). Para-aminobenzoic acid production by Staphylococci. J. Exp. Med. 79, 331.Google Scholar
Thompson, P. E. (1948). On the ability of Plasmodium lophurae to acquire resistance to chlorguanide, ‘Camoquin’ and chloroquine. J. Infect. Dis. 83, 250.Google Scholar
Thurston, J. P. (1953). The morphology of Plasmodium berghei before and after treatment with drugs. Trans. R. Soc. Trop. Med. Hyg. 47, 248.CrossRefGoogle ScholarPubMed
Williamson, J., Bertram, D. S. & Lourie, E. M. (1947). Effects of Paludrine and other antimalarials. Nature, Lond., 159, 885.Google Scholar
Williamson, J. & Lourie, E. M. (1947). Acquired Paludrine-resistance in Plasmodium gallinaceum. I. Development of resistance to Paludrine and failure to develop resistance to certain other antimalarials. Ann. Trop. Med. Parasit. 41, 278.Google Scholar
Wilson, T. & Edeson, J. F. B. (1953). Cross-resistance between ‘Daraprim’ and proguanil. Brit. med. J. 1, 731.Google Scholar